Agonist News and Research

RSS
Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

New research shows weight loss is possible without GLP-1

New research shows weight loss is possible without GLP-1

New hybrid molecule uses Trojan horse approach to treat obesity

New hybrid molecule uses Trojan horse approach to treat obesity

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Molecular keyhole discovery offers new hope for personalized pain therapies

Molecular keyhole discovery offers new hope for personalized pain therapies

Brain organoids reveal mutation-specific insights for Rett syndrome

Brain organoids reveal mutation-specific insights for Rett syndrome

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Genetic variants may reduce effectiveness of popular diabetes drugs

Genetic variants may reduce effectiveness of popular diabetes drugs

GLP-1 and dual GLP-1 / GIP drugs help lose body fat while preserving lean mass

GLP-1 and dual GLP-1 / GIP drugs help lose body fat while preserving lean mass

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

Study finds genetic basis for GLP-1 weight loss efficacy and side effects

Study finds genetic basis for GLP-1 weight loss efficacy and side effects

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

Highly potent opioid shows potential as therapy for pain and opioid use disorder

Highly potent opioid shows potential as therapy for pain and opioid use disorder

GLP-1 medications show mixed effects on body contouring outcomes

GLP-1 medications show mixed effects on body contouring outcomes

Experts propose trial to evaluate obesity medications for cancer prevention

Experts propose trial to evaluate obesity medications for cancer prevention

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

GLP-1 medications linked to reduced psychiatric hospital visits

GLP-1 medications linked to reduced psychiatric hospital visits

Study finds GLP-1 medicines cut fat while preserving muscle function

Study finds GLP-1 medicines cut fat while preserving muscle function

Weight-loss drugs linked to preterm birth risk in women with pre-existing diabetes

Weight-loss drugs linked to preterm birth risk in women with pre-existing diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.